Literature DB >> 19089637

The role of axonopathy in the mechanisms of development of demyelination processes in the central and peripheral nervous system.

Yu A Merkulov1, I A Zavalishin, D M Merkulova.   

Abstract

The role of axonopathy in the development of demyelinating processes in the CNS and peripheral nervous system was addressed in studies of 43 patients with multiple sclerosis (MS) and 144 patients with chronic inflammatory demyelinating polyneuropathy (CIDPN). Patients with MS were found to have foci of reduced MRI intensity in the T1 regime ("black holes," present in 28%) and regional atrophy of the cerebral cortex (in 46%), which showed a significant association with the degree of invalidity on the EDSS (Kendall tau = 0.38 and 0.43; p = 0.038 and 0.021, respectively). The mean fatigue score on the FSS was 4.9 (3.6; 5.4). A significant increase in the central conduction time on the background of fatigue (p = 0.016), along with an absence of signs of impaired reliability of neuromuscular transmission and an absence of past-activation phenomena, suggested that central mechanisms were predominant in the formation of fatigue phenomena in MS. In addition, 34.9% of patients with MS showed signs of peripheral nervous system involvement, while the clinical-electrophysiological pattern in 12.5% of patients with CIDPN showed signs of CNS involvement. These data widen existing concepts of the mechanisms of formation of axonopathy in the CNS, based on evidence for the development of axon-demyelinating processes in CIDPN, which is the most accessible model of demyelination for study using contemporary neurophysiological methods.

Entities:  

Mesh:

Year:  2009        PMID: 19089637     DOI: 10.1007/s11055-008-9088-0

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  19 in total

1.  Total brain N-acetylaspartate: a new measure of disease load in MS.

Authors:  O Gonen; I Catalaa; J S Babb; Y Ge; L J Mannon; D L Kolson; R I Grossman
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

2.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.

Authors:  M A van Walderveen; W Kamphorst; P Scheltens; J H van Waesberghe; R Ravid; J Valk; C H Polman; F Barkhof
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

3.  Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability.

Authors:  M Filippi; P Rossi; A Campi; B Colombo; C Pereira; G Comi
Journal:  AJNR Am J Neuroradiol       Date:  1997-09       Impact factor: 3.825

4.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

5.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Authors:  L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

6.  Fatigue in multiple sclerosis.

Authors:  L B Krupp; L A Alvarez; N G LaRocca; L C Scheinberg
Journal:  Arch Neurol       Date:  1988-04

Review 7.  Neurasthenia and chronic fatigue syndrome: the role of culture in the making of a diagnosis.

Authors:  S E Abbey; P E Garfinkel
Journal:  Am J Psychiatry       Date:  1991-12       Impact factor: 18.112

Review 8.  Fatigue associated with multiple sclerosis: diagnosis, impact and management.

Authors:  Rohit Bakshi
Journal:  Mult Scler       Date:  2003-06       Impact factor: 6.312

9.  Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment.

Authors:  R Djaldetti; I Ziv; A Achiron; E Melamed
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.